Drug Profile
RGU 825
Latest Information Update: 12 Jun 2001
Price :
$50
*
At a glance
- Originator Novartis
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 12 Jun 2001 No-Development-Reported for Type-2 diabetes mellitus in USA (Unknown route)
- 27 Apr 1998 Preclinical development for Type-2 diabetes mellitus in USA (Unknown route)